Main Menu

Why Some States’ Highly Conservative Approach to Legalizing Medical Marijuana Is Failing Patients Who Need It

Why Some States’ Highly Conservative Approach to Legalizing Medical Marijuana Is Failing Patients Who Need It

A big disappointment.

By Paul Armentano September 3, 2014

Lawmakers in nearly a dozen states in 2014 enacted legislation that promised to provide patients, particularly those suffering from intractable epilepsy, the opportunity to use cannabidiol (CBD) – a nonpsychotropic plant cannabinoid recognized for its anti-convulsant properties. The problem? So far, patients in none of these states possess the ability to legally access the compound. And there is no indication that this situation is going to change any time soon.

That is because CBD remains classified as a schedule I prohibited substance under federal law. (Congressional legislation, HR 5226, to amend CBD’s status was introduced in July.) As a result, multiple federal agencies — including the FDA, DEA, NIDA (US National Institute of Drug Abuse) and PHS (Public Health Service) — must all sign off on any clinical investigation of the non-psychotropic cannabinoid, including state-sponsored research studies. In addition, NIDA remains the sole legal provider of CBD in any FDA-approved clinical trial.

http://www.alternet.org/drugs/why-some-states-highly-conservative-approach-legalizing-medical-marijuana-failing-patients-who






Comments are Closed